Edesa Biotech, Inc. EDSA
As ofNov 17, 2026, 11:30 AM EST
- YTD
- +35.92%
- 1 year
- +10.92%
- Market cap
- 26.14M
- EPS (ttm)
- -1.72
- Shares out
- 3.47M
- Forward P/E
- -0.89
- YTD return
- +35.92%
- 1-year return
- +10.92%
- 50-day average
- 2.66
- 200-day average
- 4.02
- Volume
- 142.47K
- Avg volume
- 1.45M
- Open
- 1.86
- Previous close
- 1.89
- Day's range
- 1.85 – 1.95
- 52-week range
- 0.72 – 20.32
- Beta
- 0.84
- Price target
- 20.50 (+962.2%)
5D -0.19 (-9.27%)
Key statistics
- Enterprise value
- 4.29M
- Price / book
- 1.96
- Free cash flow
- -3.77M
- Total cash
- 2.04M
- Total debt
- 38.82K
- Return on equity
- -129.29%
- Short % of float
- 1.32%
Fundamental scorecard
5 of 25 checks passed on EDSA’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 14, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Dec 13, 2024 | Sep 1, 2024 | -0.54 | -0.29 | +0.25 | +46.30% |
| Aug 9, 2024 | Jun 1, 2024 | -0.58 | -0.52 | +0.06 | +10.34% |
| May 10, 2024 | Mar 1, 2024 | -0.69 | -0.58 | +0.11 | +15.94% |
| Feb 9, 2024 | Dec 1, 2023 | -1.21 | -0.54 | +0.67 | +55.37% |
| Dec 15, 2023 | Sep 1, 2023 | -0.71 | — | — | — |
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- edesabiotech.com
News
Edesa Biotech Receives European Commission Orphan Designation For Paridiprubart To Treat Acute Respiratory Distress Syndrome
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Pre-Market Session Edesa Biotech Enters Collaboration And License Agreement With Kyorin Pharmaceutical For Paridiprubart In Japan; Deal Valued At $140M+ With Potential Milestone Payments
12 Health Care Stocks Moving In Tuesday's After-Market Session
Your note
Sign in to keep a note on EDSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROOKS MICHAEL J PH.D. | President | Stock Award(Grant) | Aug 3, 2023 | 123,680 |
| LEMIEUX STEPHEN | Chief Financial Officer | Stock Award(Grant) | Aug 3, 2023 | 17,400 |
| NIJHAWAN PARDEEP | Chief Executive Officer | Stock Award(Grant) | Dec 1, 2024 | 603,096 |
| VAN DER VELDEN, PETER | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 9, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| CM Management, LLC | 3.17% | 110,000 | 189.89K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.60% | 20,809 | 35.92K | Sep 29, 2024 |
| Vanguard Group Inc | 0.46% | 15,864 | 27.39K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 0.33% | 11,333 | 19.56K | Sep 29, 2024 |
| Royal Bank of Canada | 0.05% | 1,737 | 3.00K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 1,016 | 1.75K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.45% | 15,702 | 27.11K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 13,060 | 22.55K | Oct 30, 2024 |
| DFA U.S. Micro Cap Series | 0.23% | 7,911 | 13.66K | Jul 30, 2024 |
| DFA U.S. Core Equity 2 Portfolio | 0.10% | 3,422 | 5.91K | Jul 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 3,059 | 5.28K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.08% | 2,825 | 4.88K | Oct 30, 2024 |
